Barclays
AGTC

Barclays’s Applied Genetic Technologies Corporation AGTC Stock Holding History

Barclays’s Portfolio AGTC Stock Details AGTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-5,590
Closed -$17K – 4903
2021
Q3 		$17K Sell
5,590
-4,110
-42% -$14.6K ﹤0.01% 4433
2021
Q2 		$38K Sell
9,700
-26,120
-73% -$108K ﹤0.01% 4263
2021
Q1 		$182K Buy
35,820
+9,467
+36% +$49.1K ﹤0.01% 3745
2020
Q4 		$108K Sell
26,353
-5,773
-18% -$28.4K ﹤0.01% 4101
2020
Q3 		$156K Sell
32,126
-4,125
-11% -$22.5K ﹤0.01% 4005
2020
Q2 		$201K Buy
+36,251
New +$166K ﹤0.01% 4068
2020
Q1 		– Sell
-7
Closed – – 6603
2019
Q4 		$0 Buy
+7
New +$22 ﹤0.01% 7000
2019
Q2 		– Sell
-84
Closed – – 7423
2019
Q1 		$0 Hold
84
– – ﹤0.01% 7450
2018
Q4 		$0 Hold
84
– – ﹤0.01% 7504
2018
Q3 		$1K Hold
84
– – ﹤0.01% 7055
2018
Q2 		$0 Hold
84
– – ﹤0.01% 7416
2018
Q1 		$0 Hold
84
– – ﹤0.01% 7442
2017
Q4 		$0 Sell
84
-10,400
-99% -$39.3K ﹤0.01% 7200
2017
Q3 		$41K Sell
10,484
-22,873
-69% -$105K ﹤0.01% 5468
2017
Q2 		$170K Buy
33,357
+19,995
+150% +$112K ﹤0.01% 4509
2017
Q1 		$92K Buy
13,362
+10,316
+339% +$80.6K ﹤0.01% 4942
2016
Q4 		$29K Buy
3,046
+2,890
+1,853% +$26K ﹤0.01% 5456
2016
Q3 		$2K Sell
156
-57
-27% -$769 ﹤0.01% 6296
2016
Q2 		$3K Sell
213
-136
-39% -$2.12K ﹤0.01% 5884
2016
Q1 		$4K Buy
349
+60
+21% +$880 ﹤0.01% 5746
2015
Q4 		$6K Buy
289
+243
+528% +$3.75K ﹤0.01% 5539
2015
Q3 		$1K Sell
46
-122
-73% -$2.02K ﹤0.01% 6642
2015
Q2 		$2K Sell
168
-4
-2% -$77 ﹤0.01% 6846
2015
Q1 		$3K Sell
172
-286
-62% -$6.39K ﹤0.01% 6792
2014
Q4 		$10K Buy
458
+399
+676% +$8.12K ﹤0.01% 6729
2014
Q3 		$1K Sell
59
-47
-44% -$851 ﹤0.01% 7548
2014
Q2 		$2K Buy
+106
New +$1.87K ﹤0.01% 7433

Other funds holding AGTC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AGA
Altrinsic Global Advisors Stamford, Connecticut $2.79B AUM 7.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Barclays's AGTC Position: Q4 2021 in Review

Barclays sold out of Applied Genetic Technologies Corporation (AGTC) in Q4 2021, closing a stake of 5,590 shares — an estimated $17K sold.

Barclays first reported a position in AGTC in Q2 2014 and held it in 27 quarters. The position peaked at $201K in Q2 2020. 55 funds tracked by Wall St. Rank hold AGTC as of Q4 2021.

  • Barclays reported no remaining Applied Genetic Technologies Corporation position as of Q4 2021 after selling out during the quarter.
  • Barclays sold 5,590 Applied Genetic Technologies Corporation shares in Q4 2021, an estimated $17K.
  • Barclays first reported a position in Applied Genetic Technologies Corporation in Q2 2014 and held it in 27 quarters.
  • Barclays's Applied Genetic Technologies Corporation position peaked at $201K in Q2 2020.
  • 55 funds tracked by Wall St. Rank held Applied Genetic Technologies Corporation as of Q4 2021.

Based on Barclays's 13F filing for Q4 2021, filed 14 Feb 2022.